Who owns Axogen, Inc. (AXGN)? Elite investor 13F holders
3 tracked elite investors reported holding Axogen, Inc as of 2026-06-30, including First Eagle Investment Management, D.E. Shaw, Mairs & Power Funds. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Health Care Equipment & Services
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| First Eagle Investment Management | AXOGEN INC | SHARE | 2026-06-30 | 2026-08-24 00:00:00 | 15754346.00 USD | 341077.000000 | Shares | reduce | Original filing |
| D.E. Shaw | AXOGEN INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 12828718.00 USD | 277738.000000 | Shares | add | Original filing |
| Mairs & Power Funds | AXOGEN INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1016180.00 USD | 22000.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.